Drug Profile
ALD 451
Alternative Names: ALD-451Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Cytomedix
- Developer Duke University Medical Center
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma